Related Experiment Video
Updated: May 23, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Novel oral anticoagulants after acute coronary syndromes
Newton B Wiggins1, Christopher B Granger, John H Alexander
1Duke University Medical Center, Durham, NC 27715, USA.
Purpose:
A number of novel oral anticoagulants, including direct thrombin inhibitors and direct factor Xa inhibitors, have been developed. This review discusses these agents and their respective clinical trials in patients with acute coronary syndromes.
Methods:
This review discusses the results of phase 2 and 3 clinical trials with novel oral anticoagulants.
Results:
Phase 2 clinical trials demonstrated that novel oral anticoagulants increase the risk of bleeding in a dose-related fashion, particularly when used in addition to dual antiplatelet therapy. What was less clear is their impact on recurrent ischemic events. In phase 3 trials, rivaroxaban was found to have a benefit on ischemic events and perhaps a greater benefit at the lower dose. The phase 3 trial with apixaban was stopped early due to increased bleeding without a meaningful reduction in ischemic events.
Conclusions:
Novel oral anticoagulants represent a promising, potentially beneficial treatment for patients with a recent acute coronary syndrome but come with a risk of bleeding. The benefits and risks of these agents will need to be carefully weighed and may depend on both patient risk and concomitant therapy. Additional research is needed to determine how to best integrate these medications into the care of patients with acute coronary syndromes.
Insights
Novel oral anticoagulants show promise for acute coronary syndrome patients but increase bleeding risk. Careful consideration of patient risk and therapy is crucial for optimal outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Novel oral anticoagulants (NOACs), including direct thrombin and factor Xa inhibitors, are emerging treatments.
- These agents offer new therapeutic options for patients with acute coronary syndromes (ACS).
Purpose of the Study:
- To review NOACs and their clinical trial data in ACS patients.
- To evaluate the efficacy and safety of NOACs in this population.
Main Methods:
- Review of Phase 2 and Phase 3 clinical trials involving NOACs.
- Analysis of trial data focusing on bleeding risk and ischemic events.
Main Results:
- Phase 2 trials indicated a dose-related increase in bleeding risk with NOACs, especially with dual antiplatelet therapy.
- Phase 3 trials showed rivaroxaban provided ischemic event benefits, while apixaban's trial was halted due to bleeding risks without significant ischemic event reduction.
Conclusions:
- NOACs present a potential benefit for ACS patients but carry a significant bleeding risk.
- Balancing NOAC benefits and risks is essential, considering individual patient factors and concurrent treatments.
- Further research is required to optimize NOAC integration into ACS care pathways.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:26Acute Coronary Syndrome V: Nursing Management